# EDGAR Filing Document

**Accession Number:** 0001671584
**File Stem:** 0000950170-25-087813
**Filing Date:** 2025-6
**Character Count:** 26777
**Document Hash:** 47dfc7813c4a99a7b04e7a8c920e57d9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-087813.hdr.sgml**: 20250618

**ACCESSION NUMBER**: 0000950170-25-087813

**CONFORMED SUBMISSION TYPE**: S-1MEF

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20250618

**DATE AS OF CHANGE**: 20250618

**EFFECTIVENESS DATE**: 20250618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aptevo Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001671584
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811567056
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-288134
- **FILM NUMBER:** 251056346

**BUSINESS ADDRESS:**
- **STREET 1:** 2401 4TH AVE.
- **STREET 2:** SUITE 1050
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121
- **BUSINESS PHONE:** 206-838-0500

**MAIL ADDRESS:**
- **STREET 1:** 2401 4TH AVE.
- **STREET 2:** SUITE 1050
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121

**As filed with the Securities and Exchange Commission on June 18, 2025**

**Registration No. 333-**

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**FORM S-1** 

**REGISTRATION STATEMENT**

***UNDER*** 

***THE SECURITIES ACT OF 1933*** 

**APTEVO THERAPEUTICS INC.**

**(Exact Name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **2834** | **81-1567056** |
| **(State or Other Jurisdiction of**<br>**Incorporation or Organization)** | **(Primary Standard Industrial**<br>**Classification Code Number)** | **(I.R.S. Employer**<br>**Identification Number)** |

---

**2401 4th Avenue, Suite 1050**

**Seattle, Washington, 98121**

**(206) 838-0500** 

**(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)** 

------

**Marvin L. White**

**President and Chief Executive Officer**

**Aptevo Therapeutics Inc.** 

**2401 4th Avenue, Suite 1050**

**Seattle, Washington, 98121**

**(206) 838-0500** 

**(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)** 

***Copies to:***

------

---

| | | |
|:---|:---|:---|
| **Sean M. Donahue**<br>**Paul Hastings LLP**<br>**2050 M Street, NW**<br>**Washington, DC 20036**<br>**(202) 551-1704** | **SoYoung Kwon**<br>**Senior Vice President and General Counsel**<br>**Aptevo Therapeutics Inc.** <br>**2401 4th Avenue, Suite 1050**<br>**Seattle, Washington, 98121**<br>**(206) 838-0500**  | **Charles E. Phillips**<br>**Ellenoff Grossman & Schole LLP**<br>**1345 Avenue of the Americas**<br>**New York, NY 10105**<br>**(212) 370-1300** |

---

**Approximate date of commencement of proposed sale to the public**: As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (333-288061)

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**This Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) under the Securities Act of 1933, as amended.** 

------

**EXPLANATORY NOTE**

This 462(b) Registration Statement relates to the reasonable best efforts public offering of securities (the "Offering") contemplated by the Registration Statement on Form S-1 (File No. 333-288061), which was initially filed with the United States Securities and Exchange Commission (the "SEC") on June 16, 2025, and which was declared effective by the SEC on June 18, 2025 (the "Prior Registration Statement").

This Registration Statement on Form S-1 is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, for the purposes of registering additional securities of the same class as were included in the Prior Registration Statement, representing an increase in the maximum aggregate offering price by $67,500, which includes $11,250 worth of shares of the Company's common stock, par value $0.001 per share ("Common Stock") and/or prefunded warrants to purchase $11,250 worth of shares of Common Stock to be issued to the investors and common warrants to purchase up to $56,250 worth of Common Stock.

The additional securities that are being registered for sale are in an amount and at a price that together represents no more than 20% of the maximum aggregate offering price set forth in Exhibit 107 to the Prior Registration Statement.

The contents of the Prior Registration Statement and all exhibits thereto are hereby incorporated by reference.

The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Exhibit Description**  |
| 5.1 | [<u>Opinion of Paul Hastings LLP.</u>](apvo-ex5_1.htm) |
| 23.1 | [<u>Consent of Moss Adams LLP, Independent Registered Public Accounting Firm.</u>](apvo-ex23_1.htm) |
| 23.2 | [<u>Consent of Paul Hastings LLP (included in Exhibit 5.1).</u>](apvo-ex5_1.htm) |
| 24.1\* | [<u>Power of Attorney.</u>](https://www.sec.gov/Archives/edgar/data/1671584/000095017025086548/apvo-2025-s1_-_june_offe.htm#signatures) |
| 107 | [<u>Filing Fee Table.</u>](apvo-exfiling_fees.htm) |
| \* | Previously filed on the signature page to the Prior Registration Statement and incorporated by reference herein. |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Seattle, State of Washington, on June 18, 2025.

---

| | | |
|:---|:---|:---|
|  | **Aptevo Therapeutics Inc.** | **Aptevo Therapeutics Inc.** |
| Date: June 18, 2025 | By: | */s/ Marvin L. White* |
|  |  | Marvin L. White |
|  |  | President and Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, as amended this registration statement has been signed by the following persons in the capacities indicated on the 18th day of June, 2025.

------

---

| | |
|:---|:---|
| **Signatures** | **Title** |
| */s/ Marvin L. White* | President, Chief Executive Officer and Director |
| **Marvin L. White** | (Principal Executive Officer) |
| \* | Senior Vice President and Chief Financial Officer  |
| **Daphne Taylor** | (Principal Financial and Accounting Officer) |
| \* | Chairman of the Board of Directors |
| **John E. Niederhuber, M.D.** |  |
| \* | Director |
| **Daniel J. Abdun-Nabi** |  |
| \* | Director |
| **Grady Grant, III** |  |
| \* | Director |
| **Zsolt Harsanyi, Ph. D.** |  |
| \* | Director |
| **Barbara Lopez Kunz** |  |

---

\* /s/ Marvin L. White Attorney-in-Fact

------

## Exhibit 5.1

![img57496738_0.jpg](img57496738_0.jpg)

**Exhibit 5.1**

June 18, 2025

Aptevo Therapeutics Inc.

2401 4th Avenue, Suite 1050

Seattle, WA 98121

Re: Registration Statement on Form S-1

Ladies and Gentlemen:

We have acted as counsel to Aptevo Therapeutics Inc., a Delaware corporation (the "Company"), in connection with the preparation and filing with the U.S. Securities and Exchange Commission (the "Commission"), pursuant to the Securities Act of 1933, as amended (the "Securities Act"), of the Registration Statement on Form S-1 of the Company (including all exhibits thereto, the "Registration Statement"), including a related prospectus filed with the Registration Statement (the "Prospectus") relating to the proposed public offering (the "Offering") of (i) up to $11,250 worth of shares (the "Shares") of the Company's common stock, $0.001 par value per share ("Common Stock"), (ii) common warrants to purchase up to $56,250 worth of shares of Common Stock (the "Common Warrants"), (iii) pre-funded warrants to purchase up to $11,250 worth of shares of Common Stock (the "Pre-Funded Warrants", and together with the Common Warrants, the "Warrants") and (iv) up to $67,500 worth of shares of Common Stock issuable from time to time upon exercise of the Warrants (the "Warrant Shares" and collectively with the Warrants and the Shares, the "Securities"). The Securities are to be sold to the several purchasers pursuant to a securities purchase agreement (the "Securities Purchase Agreement") among the Company and the purchasers signatory thereto (collectively, the "Purchasers").

This opinion letter is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.

As such counsel and for purposes of our opinions set forth herein, we have examined and relied upon originals or copies, certified or otherwise identified to our satisfaction, of such documents, resolutions, certificates and other instruments of the Company and corporate records furnished to us by the Company, and have reviewed certificates of public officials, statutes, records and such other instruments and documents as we have deemed necessary or appropriate as a basis for the opinion set forth below, including without limitation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)the Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)the form of Securities Purchase Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the Amended and Restated Certificate of Incorporation of the Company (the "Certificate of Incorporation"), certified as of June 16, 2025, by the Secretary of State of the State of Delaware and certified by an officer of the Company as of the date hereof, and the Bylaws of the Company as presently in effect (the "Bylaws", and together with the Certificate of Incorporation, the "Company Charter Documents");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) a certificate, dated as of June 16, 2025, from the Secretary of State of the State of Delaware certifying as to the existence and good standing of the Company under the laws of the State of Delaware (the "Good Standing Certificate");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)resolutions adopted by the board of directors of the Company or committee thereof, certified by an officer of the Company, relating to, among other things, the approval of the registration, sale and issuance of the Securities (the "Resolutions"); and

------

June 18, 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)a certificate executed by an officer of the Company, dated as of the date hereof, certifying to, among other things, the Company Charter Documents and the Resolutions.

In addition to the foregoing, we have made such investigations of law as we have deemed necessary or appropriate as a basis for the opinions set forth in this opinion letter. In such examination and in rendering the opinions expressed below, we have assumed, without independent investigation or verification: (i) the genuineness of all signatures on all agreements, instruments, corporate records, certificates and other documents submitted to us; (ii) the authenticity and completeness of all agreements, instruments, corporate records, certificates and other documents submitted to us as originals; (iii) that all agreements, instruments, corporate records, certificates and other documents submitted to us as certified, electronic, facsimile, conformed, photostatic or other copies conform to the originals thereof, and that such originals are authentic and complete; (iv) the legal competency, capacity and authority of all persons executing all agreements, instruments, corporate records, certificates and other documents submitted to us; (v) the due authorization, execution and delivery of all agreements, instruments, corporate records, certificates and other documents by all parties thereto (other than the Company); (vi) that no documents submitted to us have been amended or terminated orally or in writing, except as has been disclosed to us in writing; (vii) that the statements contained in the certificates and comparable documents of public officials, officers and representatives of the Company and other persons on which we have relied for the purposes of this opinion letter are true and correct on and as of the date hereof; (viii) that there has not been and there will not be any change in the good standing status of the Company from that reported in the Good Standing Certificate; (ix) that each of the officers and directors of the Company has properly exercised his or her fiduciary duties; (x) that the Securities will not be issued or transferred in violation of any restriction contained in the Certificate of Incorporation and that upon issuance of any of the Shares or Warrant Shares, the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under the Certificate of Incorporation; (xi) that at or prior to the time of the issuance and delivery of any of the Securities, the Registration Statement will have been declared effective under the Securities Act and such effectiveness shall not have been terminated or rescinded; (xii) that the exercise price of the Warrants will not be adjusted to an amount below the par value of the Common Stock; and (xiii) that the Securities Purchase Agreement to be executed by the Purchasers is in substantially the form previously provided to us to review. We have also assumed that the Securities will be issued and sold as described in the Registration Statement and in accordance with the terms of the

Securities Purchase Agreement. With respect to the Warrants and the Warrant Shares, we express no opinion to the extent that, notwithstanding the Company's current reservation of shares of Common Stock, future issuances of securities of the Company, including the Warrant Shares and/or antidilution adjustments to outstanding securities of the Company, including the Warrants, may cause the Warrants to be exercisable for more shares of Common Stock than the number that then remain authorized but unissued.

As to all questions of fact material to this opinion letter and as to the materiality of any fact or other matter referred to herein, we have relied (without independent investigation or verification) upon representations and certificates or comparable documents of officers and representatives of the Company.

Based upon the foregoing, and in reliance thereon, and subject to the assumptions, limitations, qualifications and exceptions set forth herein, we are of the opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.The Shares have been duly authorized by all necessary corporate action on the part of the Company and, when issued and sold in accordance with the Registration Statement and the Prospectus and delivered and paid for in accordance with the terms of the Securities Purchase Agreement, the Shares will be validly issued, fully paid and nonassessable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.The Warrants have been duly authorized by all necessary corporate action on the part of the Company and, when issued and sold in accordance with the Registration Statement and the Prospectus and delivered and paid for in accordance with the terms of the Securities Purchase Agreement, the Warrants will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms except as such enforceability may be limited

------

June 18, 2025

by (i) any applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors' rights generally including, without limitation, fraudulent transfer or fraudulent conveyance laws; (ii) public policy considerations, statutes or court decisions that may limit rights to obtain exculpation, indemnification or contribution (including, without limitation, indemnification regarding violations of the securities laws and indemnification for losses resulting from a judgment for the payment of any amount other than in United States dollars); and (iii) general principles of equity (including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing) and the availability of equitable remedies (including, without limitation, specific performance and equitable relief), regardless of whether considered in a proceeding in equity or at law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.The Warrant Shares have been duly authorized by all necessary corporate action on the part of the Company and, assuming a sufficient number of authorized but unissued shares of Common Stock are available for issuance when the Warrants are exercised, the Warrant Shares, when and if issued upon exercise of the Warrants in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable.

With regard to opinion paragraph 2: (i) our opinion is subject to the qualification that the availability of specific performance, an injunction or other equitable remedies is subject to the discretion of the court before which the request is brought; (ii) we express no opinion as to any provision of the Warrants, that (a) provides for liquidated damages, buy-in damages, monetary penalties, prepayment or make-whole payments or other economic remedies to the extent such provisions may constitute unlawful penalties, (b) relates to advance waivers of claims, defenses, rights granted by law, or notice, opportunity for hearing, evidentiary requirements, statutes of limitations, trial by jury, or procedural rights, (c) restricts non-written modifications and waivers, (d) provides for the payment of legal and other professional fees where such payment is contrary to law or public policy, (e) relates to exclusivity, election or accumulation of rights or remedies, (f) authorizes or validates conclusive or discretionary determinations, or (g) provides that provisions of the Warrants are severable to the extent an essential part of the agreed exchange is determined to be invalid and unenforceable; and (iii) we express no opinion as to whether a state court outside of the State of New York or a federal court of the United States would give effect to the choice of New York law provided for in the Warrants.

Without limiting any of the other limitations, exceptions, assumptions and qualifications stated elsewhere herein, we express no opinion with regard to the applicability or effect of the laws of any jurisdiction other than the Delaware General Corporation Law and the laws of the State of New York, as in effect on the date of this opinion letter. We are not rendering any opinion as to compliance with any federal or state antifraud law, rule or regulation relating to securities, or to the sale or issuance thereof.

This opinion letter deals only with the specified legal issues expressly addressed herein, and you should not infer any opinion that is not explicitly stated herein from any matter addressed in this opinion letter.

This opinion letter is rendered solely in connection with the offering of the Securities as described in the Registration Statement. This opinion letter is rendered as of the date hereof, and we assume no obligation to advise you or any other person with regard to any change after the date hereof in the circumstances or the law that may bear on the matters set forth herein, even if the change may affect the legal analysis or a legal conclusion or other matters in this opinion letter.

We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement and to the reference to our firm in the Prospectus under the heading "Legal Matters." In giving such consent, we do not hereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules or regulations of the Commission thereunder.

------

June 18, 2025

Very truly yours,

/s/ Paul Hastings LLP

------

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in this Registration Statement on Form S-1 of Aptevo Therapeutics Inc. (the "Company") of our report dated February 14, 2025, relating to the consolidated financial statements of the Company (which report expresses an unqualified opinion and includes an explanatory paragraph relating to a going concern uncertainty), appearing in the Annual Report on Form 10-K of the Company for the year ended December 31, 2024, filed with the Securities and Exchange Commission. We also consent to the reference to us under the heading "Experts" in such Registration Statement.

/s/ Moss Adams LLP

Seattle, Washington

June 18, 2025

------

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-1**

(Form Type)

**Aptevo Therapeutics Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Table 1: Newly Registered and Carry Forward Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security<br>Type** | **Security<br>Class**<br>**Title** | **Fee**<br>**Calculation**<br>**or Carry**<br>**Forward**<br>**Rule** | **Amount**<br>**Registered** | **Proposed**<br>**Maximum**<br>**Offering**<br>**Price**<br>**Per**<br>**Unit** | **Maximum**<br>**Aggregate**<br>**Offering**<br>**Price** | **Fee Rate** | **Amount of**<br>**Registration**<br>**Fee(6)** |
| Fees to Be Paid | Equity | Common stock, par value $0.001 per share | Rule 457(o) |  |  | $11250 | 0.00015310 | $2.00 |
|  | Other | Pre-funded warrants to purchase common stock | Rule 457(g) |  |  | Included above  |  |  |
|  | Other | Common warrants to purchase common stock | Rule 457(g) |  |  |  |  |  |
|  | Equity | Common stock issuable upon exercise of the common warrants | Rule 457(o) |  |  | $56250 | 0.00015310 | $9.00 |
|  | Equity | Common stock issuable upon exercise of the pre-funded warrants | Rule 457(o) |  |  | Included above  |  |  |
| Fees Previously Paid |  |  |  |  |  |  |  |  |
| Carry Forward Securities |  |  |  |  |  |  |  |  |
| **Total Offering Amounts** |  |  |  |  |  | $67500 | 0.00015310 | $11.00 |
| **Total Fees Previously Paid** |  |  |  |  |  |  |  |  |
| **Total Fee Offsets** |  |  |  |  |  |  |  |  |
| **Net Fee Due** |  |  |  |  |  |  |  | $11.00 |

---

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), there are also being registered such additional securities that may be issued because of events such as recapitalizations, stock dividends, stock splits and reverse stock splits, and similar transactions.

(2) Estimated solely for the purpose of determining the amount of the registration fee in accordance with Rule 457(o) under the Securities Act. Represents only the additional shares of the Registrant's common stock being registered. Does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1 (File No. 333-288061) (the "Prior Registration Statement"), which was declared effective by the United States Securities and Exchange Commission on June 18, 2025.

(3) The proposed maximum aggregate offering price of the shares of common stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the aggregate offering price of the pre-funded warrants offered and sold in the offering (plus the aggregate exercise price of the shares of common stock issuable upon exercise of the pre-funded warrants). In accordance with Rule 462(b) under the Securities Act of 1933, as amended, an additional amount of securities having the proposed maximum aggregate offering price of $11,250 is hereby registered.

(4) No fee due pursuant to Rule 457(g) under the Securities Act because the warrants are being registered in the same registration statement as the common stock issuable upon exercise of the warrants.

(5) There will be issued five common warrants, each to purchase one share of common stock, for every share of common stock being offered in this offering. As estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act, the proposed maximum offering price of the additional shares of common stock issuable upon exercise of the common warrants proposed to be sold in the offering on this registration statement is $56,250, which is equal to 500% of $11,250, as each share of common stock and pre-funded warrant is being offered with five common warrants, each to purchase one share of common stock at an exercise price equal to 100% of the purchase price per share of common stock.

(6) The Registrant previously registered an aggregate of $8,000,000 of its securities on the Prior Registration Statement, for which the Registrant previously paid a filing fee of $7,349.00.

------